|Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.||Interim CEO & Chairman||85.64k||N/A||1958|
|Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law||Chief Financial Officer||292.45k||N/A||1962|
|Mr. Harry Simeonidis||Pres of Asia Pacific||354.71k||N/A||1969|
|Ms. Victoria Gavrilenko||Operations Mang.||N/A||N/A||1983|
|Mr. Alex Arzeno||VP of Investor Relations||N/A||N/A||N/A|
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
GBS Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.